2[1]The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med, 1993,329: 977-986.
3[2]UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylurea or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes. Lancet, 1998,325: 837-853.
4[3]Ruilope LM, Luno J. Angiotensin blockade in type 2 diabetic renal disease. Kidney Int Suppl, 2002,82:61-63.
5[4]Pahor M, Psaty BM, Alderman MH, et al. Therapeutic benefits of ACE inhibitors and other antihypertensive drugs in patients with type 2 diabetes. Diabetes Care, 2000,23:888-892.
6[5]Fried LF, Qrchard TJ, Kasiske BL, et al. Effect of lipid reduction on the progression of renal diseases: a meta-analysis. Kidney Int, 2001,59:260-269.
7[8]Brenner BM, Cooper ME, de Zeeuw D, et al. Effect of losartan on renal and cardiovascular outcome in patients with type 2 diabetes and nephropathy. N Engl J Med,2001,345: 861-869.
8[9]Parving HH, Lehnert H, Brochner-Mortensen J, et al.The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med,2001,345: 870-878.
9Lim,A.K.,Tesch,G.H..Inflammation in diabetic nephropathy[J].Mediators Inflamm,2012,21(8):146-154.
10Hagiwara,S.,Kantharidis,P.,Cooper,M.E..What are new avenuesfor renal protection,in addition to RAAS inhibition[J].Curr Hyper-tens Rep,2012,14(2):100-110.
